Date published: 2026-7-21

1-800-457-3801

SCBT Portrait Logo
Seach Input

claudin-18 CRISPR/Cas9 KO Plasmid (h): sc-404431

0.0(0)
Write a reviewAsk a question

Datasheets
  • Target species: human
  • 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
  • claudin-18 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
  • gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the claudin-18 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
  • The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
    Gene Editing Promo Banner

    Ordering Information

    Product NameCatalog #UNITPriceQtyFAVORITES

    claudin-18 CRISPR/Cas9 KO Plasmid (h)

    sc-404431
    20 µg
    $397.00

    Overview

    CLDN18 encodes claudin-18, a tetraspan tight-junction protein that contributes to paracellular barrier function and epithelial polarity in tissue-specific contexts, including gastric and pulmonary epithelia. By organizing tight junction strands with other claudins and scaffold proteins such as ZO family members, claudin-18 helps regulate junctional integrity, ion selectivity, and signaling linked to cytoskeletal dynamics. Altered CLDN18 expression or junctional localization is associated with epithelial remodeling and dysregulated barrier homeostasis, processes often connected to inflammation and tumor biology. CLDN18 has also been studied in the context of fusion events and lineage programs that impact cell adhesion and differentiation states.

    claudin-18 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the CLDN18 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the CLDN18 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.

    The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the CLDN18 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish claudin-18 protein expression.

    This CRISPR knockout system enables efficient generation of CLDN18-deficient cell models for investigation of claudin-18 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.

    Key Features

    • sgRNAs targeting CLDN18 exon(s) critical for claudin-18 function
    • Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
    • GFP reporter for identification of transfected cells
    • Pool of plasmids targeting multiple CLDN18 genomic sites to improve knockout efficiency
    • Compatible with delivery by transfection

    Design Variants

    CRISPRs +/- HDRs

    • gRNAs encoded by claudin-18 CRISPR/Cas9 KO Plasmid (h) and claudin-18 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the CLDN18 locus. One or both targeting designs may be available. See Related Products for availability.
    • HDR donor constructs encoded by claudin-18 HDR Plasmid (h) and claudin-18 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by CLDN18 homology arms to support homology-directed repair at defined CLDN18 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.

    For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.